These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 18195709)

  • 1. BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours.
    D'Arcy V; Pore N; Docquier F; Abdullaev ZK; Chernukhin I; Kita GX; Rai S; Smart M; Farrar D; Pack S; Lobanenkov V; Klenova E
    Br J Cancer; 2008 Feb; 98(3):571-9. PubMed ID: 18195709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression.
    Akhtar MS; Akhter N; Talat A; Alharbi RA; Sindi AAA; Klufah F; Alyahyawi HE; Alruwetei A; Ahmad A; Zamzami MA; Deo S; Husain SA; Badi OA; Khan MJ
    Oncotarget; 2023 May; 14():528-541. PubMed ID: 37235839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.
    Renaud S; Pugacheva EM; Delgado MD; Braunschweig R; Abdullaev Z; Loukinov D; Benhattar J; Lobanenkov V
    Nucleic Acids Res; 2007; 35(21):7372-88. PubMed ID: 17962299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of brother of the regulator of imprinted sites in peripheral blood neutrophils is associated with both benign and malignant breast lesions.
    El-Sharkawy NM; Radwan WM; Essa ES; Kandeel EZ; Abd El-Fattah EK; Kandil SH; Kamel AM
    Cytometry B Clin Cytom; 2017 Sep; 92(5):355-360. PubMed ID: 27219508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
    Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
    Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the cancer-testis antigen BORIS correlates with prostate cancer.
    Cheema Z; Hari-Gupta Y; Kita GX; Farrar D; Seddon I; Corr J; Klenova E
    Prostate; 2014 Feb; 74(2):164-76. PubMed ID: 24123052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
    Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
    Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
    Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
    Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcription factor BORIS (Brother of the Regulator of Imprinted Sites) directly induces expression of a cancer-testis antigen, TSP50, through regulated binding of BORIS to the promoter.
    Kosaka-Suzuki N; Suzuki T; Pugacheva EM; Vostrov AA; Morse HC; Loukinov D; Lobanenkov V
    J Biol Chem; 2011 Aug; 286(31):27378-88. PubMed ID: 21659515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of BORIS detected in the leukocytes of breast cancer patients as an early marker of tumorigenesis.
    D'Arcy V; Abdullaev ZK; Pore N; Docquier F; Torrano V; Chernukhin I; Smart M; Farrar D; Metodiev M; Fernandez N; Richard C; Delgado MD; Lobanenkov V; Klenova E
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5978-86. PubMed ID: 17062669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
    Alberti L; Losi L; Leyvraz S; Benhattar J
    PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAGEA1 inhibits the expression of BORIS via increased promoter methylation.
    Zhao J; Wang Y; Liang Q; Xu Y; Sang J
    J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structural complexity of the human BORIS gene in gametogenesis and cancer.
    Pugacheva EM; Suzuki T; Pack SD; Kosaka-Suzuki N; Yoon J; Vostrov AA; Barsov E; Strunnikov AV; Morse HC; Loukinov D; Lobanenkov V
    PLoS One; 2010 Nov; 5(11):e13872. PubMed ID: 21079786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
    Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
    Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells.
    Tiffen JC; Bailey CG; Marshall AD; Metierre C; Feng Y; Wang Q; Watson SL; Holst J; Rasko JE
    Int J Cancer; 2013 Oct; 133(7):1603-13. PubMed ID: 23553099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.
    Hines WC; Bazarov AV; Mukhopadhyay R; Yaswen P
    PLoS One; 2010 Mar; 5(3):e9738. PubMed ID: 20305816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.
    Klenova EM; Morse HC; Ohlsson R; Lobanenkov VV
    Semin Cancer Biol; 2002 Oct; 12(5):399-414. PubMed ID: 12191639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BORIS, brother of the regulator of imprinted sites, is aberrantly expressed in hepatocellular carcinoma.
    Chen K; Huang W; Huang B; Wei Y; Li B; Ge Y; Qin Y
    Genet Test Mol Biomarkers; 2013 Feb; 17(2):160-5. PubMed ID: 23237599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolution of epigenetic regulators CTCF and BORIS/CTCFL in amniotes.
    Hore TA; Deakin JE; Marshall Graves JA
    PLoS Genet; 2008 Aug; 4(8):e1000169. PubMed ID: 18769711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of Msx2 gene expression by steroid hormones in human nonmalignant and malignant breast cancer explants cultured in vitro.
    Malewski T; Milewicz T; Krzysiek J; Gregoraszczuk EL; Augustowska K
    Cancer Invest; 2005; 23(3):222-8. PubMed ID: 15945508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.